[A22-110] Faricimab (neovascular age-related macular degeneration) – Benefit assessment according to § 35a Social Code Book V
Last updated 16.01.2023
Project no.:
A22-110
Commission:
Commission awarded on 14.10.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Head and nerves
Indication:
Adult patients with neovascular (wet) age-related macular degeneration
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-109 | Faricimab (visual impairment due to diabetic macular oedema) – Benefit assessment acc. to § 35a Social Code Book V | Commission completed |